Dynavax Technologies Share Holder Equity 2010-2022 | DVAX

Dynavax Technologies share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Dynavax Technologies Annual Share Holder Equity
(Millions of US $)
2021 $222
2020 $59
2019 $8
2018 $63
2017 $200
2016 $89
2015 $187
2014 $100
2013 $186
2012 $115
2011 $100
2010 $52
2009 $6
Dynavax Technologies Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $287
2021-12-31 $222
2021-09-30 $68
2021-06-30 $83
2021-03-31 $100
2020-12-31 $59
2020-09-30 $69
2020-06-30 $58
2020-03-31 $12
2019-12-31 $8
2019-09-30 $39
2019-06-30 $11
2019-03-31 $43
2018-12-31 $63
2018-09-30 $97
2018-06-30 $131
2018-03-31 $166
2017-12-31 $200
2017-09-30 $204
2017-06-30 $141
2017-03-31 $97
2016-12-31 $89
2016-09-30 $108
2016-06-30 $139
2016-03-31 $164
2015-12-31 $187
2015-09-30 $211
2015-06-30 $75
2015-03-31 $75
2014-12-31 $100
2014-09-30 $122
2014-06-30 $151
2014-03-31 $174
2013-12-31 $186
2013-09-30 $72
2013-06-30 $85
2013-03-31 $98
2012-12-31 $115
2012-09-30 $130
2012-06-30 $145
2012-03-31 $88
2011-12-31 $100
2011-09-30 $36
2011-06-30 $46
2011-03-31 $36
2010-12-31 $52
2010-09-30 $23
2010-06-30 $13
2010-03-31 $-2
2009-12-31 $6
2009-09-30 $18
2009-06-30 $25
2009-03-31 $20
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.637B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00